Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD-1211 in Subjects With Opioid-Induced Constipation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Axelopran (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors Theravance
- 26 Apr 2013 Status changed from active, no longer recruiting to completed, as indicated in a Theravance media release.
- 01 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2012 Planned End Date changed from 1 Oct 2011 to 1 May 2012 as reported by ClinicalTrials.gov.